Obsidian Therapeutics Inc.
OBXHealthcare|Biotechnology|US
$13.87
+4.26 (+44.43%)
Ownership Breakdown
1.0M
Shares Outstanding
0.5M
Float Shares
Major Holders (25)
Combined: 105.6%
Holders of 5%+ from their latest Schedule 13D/13G filing in the last two years. Percentages are as of each filing date.
| Holder | Type | % of Class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| RA Capital Management, L.P. | IA, PN | 9.70% | 5,957,103 | Aug 10, 2026 | 13D/G |
| Peter Kolchinsky | HC, IN | 9.70% | 5,957,103 | Aug 10, 2026 | 13D/G |
| Rajeev Shah | HC, IN | 9.70% | 5,957,103 | Aug 10, 2026 | 13D/G |
| RA Capital Healthcare Fund, L.P. | Partnership | 8.00% | 4,951,187 | Aug 10, 2026 | 13D/G |
| Paradigm BioCapital Advisors GP LLC | Other | 6.60% | 4,101,576 | Oct 5, 2026 | 13D/G |
| Senai Asefaw, M.D. | Individual | 6.60% | 4,101,576 | Oct 5, 2026 | 13D/G |
| Paradigm BioCapital Advisors LP | Partnership | 6.60% | 4,101,576 | Oct 5, 2026 | 13D/G |
| Paradigm BioCapital International Fund Ltd. | Corporation | 5.90% | 3,613,771 | Oct 5, 2026 | 13D/G |
| Deep Track Capital, LP | IA, OO | 5.37% | 3,315,605 | Aug 11, 2026 | 13D/G |
| David Kroin | HC, IN | 5.37% | 3,315,605 | Aug 11, 2026 | 13D/G |
| Novo Holdings A/S | Corporation | 5.10% | 3,123,992 | Aug 10, 2026 | 13D/G |
| Deep Track Biotechnology Master Fund, Ltd. | Corporation | 5.06% | 3,122,864 | Aug 11, 2026 | 13D/G |
| Atlas Venture Fund X, L.P. | Partnership | 4.30% | 2,642,587 | Aug 10, 2026 | 13D/G |
| Atlas Venture Associates X, L.P. | Partnership | 4.30% | 2,642,587 | Aug 10, 2026 | 13D/G |
| Atlas Venture Associates X, LLC | Other | 4.30% | 2,642,587 | Aug 10, 2026 | 13D/G |
| Atlas Venture Opportunity Fund I, L.P. | Partnership | 1.70% | 1,069,278 | Aug 10, 2026 | 13D/G |
| Atlas Venture Associates Opportunity I, L.P. | Partnership | 1.70% | 1,069,278 | Aug 10, 2026 | 13D/G |
| Atlas Venture Associates Opportunity I, LLC | Other | 1.70% | 1,069,278 | Aug 10, 2026 | 13D/G |
| Atlas Venture Opportunity Fund II, L.P. | Partnership | 0.90% | 582,960 | Aug 10, 2026 | 13D/G |
| Atlas Venture Associates Opportunity II, L.P. | Partnership | 0.90% | 582,960 | Aug 10, 2026 | 13D/G |
| Atlas Venture Associates Opportunity II, LLC | Other | 0.90% | 582,960 | Aug 10, 2026 | 13D/G |
| Deep Track Special Opportunities Fund, LP. | Partnership | 0.31% | 192,741 | Aug 11, 2026 | 13D/G |
| Atlas Venture Opportunity Fund III, L.P. | Partnership | 0.30% | 208,324 | Aug 10, 2026 | 13D/G |
| Atlas Venture Associates Opportunity III, L.P. | Partnership | 0.30% | 208,324 | Aug 10, 2026 | 13D/G |
| Atlas Venture Associates Opportunity III, LLC | Other | 0.30% | 208,324 | Aug 10, 2026 | 13D/G |
Insider Trades (30)
| Insider | Position | Date | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| ROSS ROBERT W. | director | Aug 3, 2026 | AWARD | 37,653 | $12.00 | $451.8K | Form 4 |
| Norkunas Matthew | director | Aug 3, 2026 | AWARD | 37,653 | $12.00 | $451.8K | Form 4 |
| Jagasia Madan | director, officer: Chief Executive Officer | Aug 3, 2026 | AWARD | 37,653 | $12.00 | $451.8K | Form 4 |
| Barrett Peter | director | Aug 3, 2026 | AWARD | 37,653 | $12.00 | $451.8K | Form 4 |
| Hagen Heidi | director | Aug 3, 2026 | AWARD | 37,653 | $12.00 | $451.8K | Form 4 |
| Fardis Maria | director | Aug 3, 2026 | AWARD | 37,653 | $12.00 | $451.8K | Form 4 |
| Barrett Peter | Aug 3, 2026 | OTHER | 0 | — | — | Form 4 | |
| Fardis Maria | director | Aug 3, 2026 | OTHER | 355,000 | $0.78 | $276.9K | Form 4 |
| Fardis Maria | director | Aug 3, 2026 | OTHER | 290,000 | $0.78 | $226.2K | Form 4 |
| Fardis Maria | director | Aug 3, 2026 | OTHER | 80,000 | $0.78 | $62.4K | Form 4 |
| Fardis Maria | director | Aug 3, 2026 | OTHER | 497,500 | $0.78 | $388.1K | Form 4 |
| Feder Julie B | Chief Financial Officer | Aug 3, 2026 | OTHER | 2,732,337 | $0.78 | $2.1M | Form 4 |
| Feder Julie B | Chief Financial Officer | Aug 3, 2026 | OTHER | 271,604 | $0.78 | $211.9K | Form 4 |
| Hagen Heidi | director | Aug 3, 2026 | OTHER | 180,000 | $0.78 | $140.4K | Form 4 |
| Hagen Heidi | director | Aug 3, 2026 | OTHER | 337,500 | $0.78 | $263.3K | Form 4 |
| Jagasia Madan | director, officer: Chief Executive Officer | Aug 3, 2026 | OTHER | 7,081,478 | $0.78 | $5.5M | Form 4 |
| Jagasia Madan | director, officer: Chief Executive Officer | Aug 3, 2026 | OTHER | 55,324 | $0.78 | $43.2K | Form 4 |
| Jagasia Madan | director, officer: Chief Executive Officer | Aug 3, 2026 | OTHER | 110,648 | $0.78 | $86.3K | Form 4 |
| Jagasia Madan | director, officer: Chief Executive Officer | Aug 3, 2026 | OTHER | 442,592 | $0.78 | $345.2K | Form 4 |
| Jagasia Madan | director, officer: Chief Executive Officer | Aug 3, 2026 | OTHER | 4,154,000 | $0.78 | $3.2M | Form 4 |
| Norkunas Matthew | director | Aug 3, 2026 | OTHER | 0 | — | — | Form 4 |
| Norkunas Matthew | director | Aug 3, 2026 | OTHER | 180,000 | $0.78 | $140.4K | Form 4 |
| Norkunas Matthew | director | Aug 3, 2026 | OTHER | 51,563 | $0.78 | $40.2K | Form 4 |
| Hari Parameswaran | Chief Medical Officer | Aug 3, 2026 | OTHER | 1,770,369 | $0.78 | $1.4M | Form 4 |
| Hari Parameswaran | Chief Medical Officer | Aug 3, 2026 | OTHER | 48,685 | $0.78 | $38.0K | Form 4 |
| Hari Parameswaran | Chief Medical Officer | Aug 3, 2026 | OTHER | 97,370 | $0.78 | $75.9K | Form 4 |
| Hari Parameswaran | Chief Medical Officer | Aug 3, 2026 | OTHER | 943,500 | $0.78 | $735.9K | Form 4 |
| ROSS ROBERT W. | director | Aug 3, 2026 | OTHER | 180,000 | $0.71 | $127.8K | Form 4 |
| ROSS ROBERT W. | director | Aug 3, 2026 | OTHER | 175,000 | $0.78 | $136.5K | Form 4 |
| ROSS ROBERT W. | director | Aug 3, 2026 | OTHER | 162,500 | $0.78 | $126.8K | Form 4 |